Clinical trial

Genetic Determinants of Kidney Disease in People of African Ancestry With HIV

Active, not recruiting · Not applicable · 1 countries · Registry ID NCT05685810

Active, not recruitingNot applicableObservational

What this study is about

Black ethnicity is a major risk factor for chronic kidney disease \[CKD\] in people with HIV infection, suggesting that genetic factors are an important determinant of kidney disease progression in this population. The Gen-Africa study was established in 2018 to allow the study of genetic and clinical risk factors for CKD in people with HIV in the UK. Just over 3000 people across 15 sites were enrolled between May 2018 and January 2020. Demographic and clinical information was collected, and biological samples (buffy coats, plasma and urine) obtained. Cross-sectional analyses have revealed that participants of West-African ancestry are at higher risk of CKD and end-stage kidney disease \[ESKD\], and that genetic variants in the apolipoprotein L1 (APOL1) gene and sickle cell trait (SCT) are predictors of CKD and ESKD. The pathogenesis of APOL1- and SCT-associated CKD is incompletely understood, and additional, longitudinal data will be collected to improve understanding of the contribution of demographic, traditional CKD (diabetes, hypertension, obesity/metabolic syndrome, cardiovascular disease) and HIV (immuno-virological and hepatitis B/C co-infection status, antiretroviral medications) risk factors as well as additional genetic and epigenetic markers.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot listed

ConditionHIV Nephropathy, Kidney Injury, Kidney Diseases, Diabetes Mellitus, Obesity, Cardiovascular Diseases, Genetic Predisposition to Disease

Full registry criteria

Inclusion Criteria: * HIV positive * Black ethnicity (self-identified) * Informed consent Exclusion Criteria: * None

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Kidney disease2018-2030

Incidence and predictors of end-stage kidney disease, chronic kidney disease, HIVAN, focal and segmental glomerulosclerosis (FSGS), tenofovir disoproxil fumarate (TDF)-associated kidney injury.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

King's College Hospital NHS Foundation Trust🇬🇧 London, United Kingdom

Open map